≡ Risteys
R8

Documentation Changelog GitHub Contact & Feedback

Use of levodopa decarbozylase inhibitor

PheWeb

PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR

No definition available.

Endpoint definition

↥
FinnGen phenotype data

356077 individuals

diagram downward connector

Apply sex-specific rule None

356077

diagram downward connector

Check conditions None

356077

diagram downward connector
diagram bullet

Filter registries

Medicine purchases: ATC N04BA02

3799

diagram downward connector

Check pre-conditions, main-only, mode, ICD version None

2940

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

2940

diagram downward connector

Include endpoints None

2940

diagram downward connector
PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 2940 1182 1758
Unadjusted prevalence (%) 0.83 0.60 1.12
Mean age at first event (years) 68.91 67.79 69.67

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.08 4.73 [3.92, 5.72] 3.9e-58 973
15 years 0.02 2.53 [2.16, 2.97] 5.1e-30 470
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR – Use of levodopa decarbozylase inhibitor
GWS hits:

Survival analyses between endpoints

↥

Plot

before Use of levodopa decarbozylase inhibitor
after Use of levodopa decarbozylase inhibitor

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Use of levodopa decarbozylase inhibitor

↥